Second International Congress Drug Therapy in HIV Infection 18-22 November 1994 Glasgow, UK

THERAPEUTIC VACCINS

Eric Sandström
Department of Dermatovenereol. South Hospital, Stockholm, Sweden

Int Cong Drug Therapy HIV 1994 Nov 18-22;2:Abstract No. 15.2
AIDS 1994, Vol. 8 (Suppl. 4);S13

Current antiretroviral therapy is unable to give but a shortlived therapeutic response. Given that the prolonged nature of HIV-infection in part is due to an efficient immune response and that there are ways to strengthen that immune response a number of approaches have been tried, including vaccinations with HIV-gene products. In that category two main approaches are currently being evaluated. One is focused on envelope depleted inactivated HIV-particles and the other on the envelope proteins. With both approaches it has been demonstrated that the immune response to HIV can be modified in the infected host, in spite of a considerable infectious viral burden. With the former approach an augmented cell mediated response to HIV proteins is observed, which is thought to be especially important for the control of the HIV-infection. With the latter approach it is likewise demonstrated that cell mediated responses can be observed. This includes responses to HIV-proteins and other unrelated viral and bacterial proteins. This response is long lasting and can be sustained by booster immunizations. Cytotoxic T-cells have been induced. In addition functional antibodies, neutralizing and ADCC have been induced but antibodies to HLA peptides have been unaltered or reduced. In phase 1 trials stabilisation or even transient rise in CD 4 cells has been observed in those immunized. So far there has not been demonstrated a substantial reduction in the viral load in the periferal circulation. In order to evaluate these data a number of phase 2/3 trials have been initiated to study the potential clinical effect of the various immunogens.

Presenting author: Eric Sandstrom

1994-11-18
15.2

Originally published in AIDS Volume 8, Supplement 4 and hosted with permission of the publisher Lippincott Williams & Wilkins, 250 Waterloo Road, London, SE1 8RD, UK. Tel: +44 (0)20 7981 0700 Fax: +44 (0) 7981 0701

Copyright © 1994 - Lippincott Williams & Wilkins. All rights reserved. All abstracts from the 2nd International Congress Drug Therapy in HIV Infection, appearing on the AEGiS web site, are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, or otherwise published without the prior written permission of Lippincott Williams & Wilkins. You may not alter or remove any trademark, copyright or other notice. However, provided that you maintain all copyright and other notices contained therein, you may download material (one machine readable copy and one print copy per page) for your personal, non-commercial use only.

http://www.aidsonline.com http://www.ovid.com